Newsroom

Download PDF Preclinical Data from the Company’s FGFR Antibody Program also Presented CAMBRIDGE, Mass. & BERLIN, Nov 19, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data from AVEO’s anti-RON antibody program which demonstrated the successful identification of antibodies with

Download PDF Preclinical Data Presented Demonstrates that Combining Tivozanib with Chemotherapy Regimens Inhibits Breast Tumor Growth and Prevents Development of Resistance CAMBRIDGE, Mass. & BERLIN, Nov 18, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced results from a Phase 1b clinical

Download PDF Trial to Evaluate Tivozanib in Combination with Widely-Used Oral Xeloda® in Patients with Advanced Breast and Colorectal Cancers CAMBRIDGE, Mass., Nov 16, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center

Download PDF Tivozanib Data Also Presented at Annual Chemotherapy Foundation Symposium CAMBRIDGE, Mass., Nov 10, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company’s lead product candidate, tivozanib, a highly

Download PDF Current Financial Position Supports Expanding and Accelerating Clinical Development Plans for Tivozanib CAMBRIDGE, Mass., Nov 04, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced updated financial guidance and third quarter financial results, as well as recent developments. “During the

Download PDF AVEO to Present at Windhover’s Annual Therapeutic Area Partnerships Meeting CAMBRIDGE, Mass., Nov 03, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that its lead product candidate, tivozanib, has been selected as one of Windhover’s “2011 Top 10 Oncology

Download PDF Proceeds to Fund Expanding and Accelerating Clinical Development Plans for Tivozanib CAMBRIDGE, Mass., Oct 29, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the execution of a securities purchase agreement with a select group of institutional and accredited investors

Download PDF CAMBRIDGE, Mass., Oct 21, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that financial results for the company’s third quarter ended September 30, 2010 will be released before the market opens on Thursday, November 4, 2010. The AVEO management